NTLA

Intellia Therapeutics, Inc.

32.69 USD
+0.03 (+0.09%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Intellia Therapeutics, Inc. stock is up 29.26% since 30 days ago. The next earnings date is May 2, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 37.5% of the previous 7 March’s closed higher than February. In the last 10 Unusual Options Trades, there were 1 PUT, 9 CALLs. 34% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
27 Feb 19:32 20 Sep, 2024 30.00 PUT 199 290
27 Feb 19:40 15 Mar, 2024 30.00 CALL 140 1620
27 Feb 20:01 15 Mar, 2024 30.00 CALL 104 1620
28 Feb 14:35 15 Mar, 2024 30.00 CALL 200 1873
28 Feb 14:38 19 Apr, 2024 30.00 CALL 100 802
28 Feb 17:52 19 Apr, 2024 35.00 CALL 100 1757
28 Feb 20:56 19 Jul, 2024 45.00 CALL 99 1050
29 Feb 16:19 15 Mar, 2024 20.00 CALL 100 131
01 Mar 18:01 15 Mar, 2024 20.00 CALL 20 51
01 Mar 19:03 19 Apr, 2024 35.00 CALL 88 1596

About Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis. The firm has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells.

  • Goldman Sachs
    Fri Feb 23, 13:33
    hold
    downgrade
  • Canaccord Genuity
    Fri Feb 23, 09:53
    buy
    confirm
  • Wolfe Research
    Thu Feb 15, 06:29
    hold
    initial